Irsogladine

In today's world, Irsogladine has become a topic of great relevance and interest to a wide range of people. Whether we are talking about Irsogladine as a public figure, a historical event related to Irsogladine, or a topic of current debate, the importance of delving into its meaning and repercussions is undeniable. In this article, we will delve into the world of Irsogladine and explore its different facets, to understand its importance and impact on contemporary society.

Irsogladine
Names
Preferred IUPAC name
6-(2,5-Dichlorophenyl)1,3,5-triazine-2,4-diamine
Other names
DCPDAT, Dicloguamine, MN-1695.
Identifiers
ChemSpider
UNII
Properties
C9H7Cl2N5
Molar mass 256.09 g·mol−1
Pharmacology
A02BX16 (WHO)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).

Irsogladine is a phosphodiesterase inhibitor.[1]

Synthesis

ChemDrug Synthesis:[2][3] Patent:[4]

2,4-Dichloro-6-(2,5-dichlorophenyl)-1,3,5-triazine (1) (2) Dicyandiamide (3) 2,5-Dichlorobenzonitrile (4)

References

  1. ^ Satoh, H; Amagase, K; Takeuchi, K (2013). "Mucosal protective agents prevent exacerbation of NSAID-induced small intestinal lesions caused by antisecretory drugs in rats". The Journal of Pharmacology and Experimental Therapeutics. 348 (2): 227–35. doi:10.1124/jpet.113.208991. PMID 24254524. S2CID 23740642.
  2. ^ Serradell, MN; Blancafort, P.; Castaer, J.; MN-1695. Drugs Fut 1983, 8, 6, 502.
  3. ^ Ueda F, Aratani S, Mimura K, Kimura K, Nomura A, Enomoto H. Effect of 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate (MN-1695) on gastric ulcers and gastric secretion in experimental animals. Arzneimittelforschung. 1984;34(4):474-7. PMID: 654016.
  4. ^ DE2506814 idem Hiromu Murai, 6 More », U.S. patent 3,966,728 (1976 to Nippon Shinyaku Co., Ltd.).


Stub icon

This article about an organic compound is a stub. You can help Wikipedia by expanding it.

Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.